Merck (MRK) Stock Soars 10% as Cancer Vaccine Delivers a Historic First
TLDR
- Merck and Moderna’s Phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival in melanoma patients
- The trial enrolled 1,137 high-risk Stage IIB-IV melanoma patients and is the first large-scale Phase 3 win for mRNA-based cancer vaccines
- MRK stock hit a new 52-week high of $143.52 in premarket trading, up around 10%
- Moderna surged over 90% premarket, trading at $118.61
- Barclays analysts estimate the therapy could generate around $3 billion in melanoma sales by 2035
Merck stock jumped roughly 10% in premarket trading on Wednesday after the company and Moderna announced a major clinical win for their personalized mRNA cancer vaccine.
The Phase 3 INTerpath-001 trial of Intismeran autogene, combined with Keytruda, met its primary endpoint of recurrence-free survival and the secondary endpoint of distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma.
MRK hit $143.52 in premarket trade, a new 52-week high, clearing the prior ceiling of $137.98.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
